Jens Thomas Siveke

This study identifies LOY as a driver of aggressive PDAC through epigenetic reprogramming, linking it to EMT and metastasis, and highlights its clinical relevance as a biomarker.

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

This study uses multimodal single-cell profiling to identify immune cell crosstalk mechanisms in poor prognostic cholangiocarcinoma, revealing key ligand pairs and pathways contributing to immune exhaustion.

This paper develops a radio-theranostic approach targeting LRRC15 to image and treat cancer, showing tumor reduction and reversal of immunotherapy resistance.

This study identifies KDM5B's role in regulating the PRDX/TXN ROS detoxification system in melanoma DTPs, showing that PRDX inhibition increases ROS vulnerability and delays resistance to MAPK inhibition.

This study identifies ATR inhibitors as synergistic with gemcitabine in killing PDAC cells by blocking the DNA damage response pathway.

The paper develops a machine learning model using radiomic features from MRI to predict survival and tumor subtype in pancreatic ductal adenocarcinoma with high accuracy.

This paper develops a machine learning model to predict molecular subtypes of PDAC from radiomic features, showing differential chemotherapy response based on subtype.